Clinical trials: Depression
Psoriatic Arthritis
Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.
- Trial name
- NCT00884468
- Where
- Spain
- Volunteers
- 384 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder (MDD)
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
- Trial name
- NCT06796868
- Testing
- GW117 Tablets
- Where
- 17 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Respiratory Depression
Clinical Utility of Capnography in the PACU( Post-anaesthesia Care Unit)
Multi-center observational trial with study device blinded in order to assess in parallel standard monitoring and intervention practices related to management of respiratory compromise in the post-anaesthesia care unit (PACU)
- Trial name
- NCT02707003
- Where
- 2 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Medtronic - MITG
Depressive Disorder, Treatment-Resistant
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate…
- Trial name
- NCT02153502
- Testing
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Where
- 32 sites in United States
- Volunteers
- 206 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in…
- Trial name
- NCT00531622
- Testing
- saredutant (SR48968), escitalopram
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Depressive Disorder
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03395353
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Shionogi
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Depression, Anxiety
Meru Health Program for Cancer Patients With Depression and Anxiety
The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP).
- Trial name
- NCT05588622
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Meru Health, Inc.
Chronic Pain, Anxiety
Phase II Trial of Nu-V3 Non-Invasive Nerve Stimulation Device for Chronic Pain, Anxiety, Depression, Sleeplessness
This Nu-V3 clinical study is a randomized, phase II, open-label study evaluating the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.
- Conditions
- Chronic Pain, Anxiety, Depression, Sleeplessness
- Trial name
- Nu-V3P2RCT (NCT05394545)
- Testing
- Nu-V3
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nu-Life Solutions
Depression, Bipolar
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the…
- Trial name
- NCT00191399
- Testing
- Olanzapine, Fluoxetine
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Congestive Heart Failure
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
- Trial name
- NCT00634309
- Testing
- Candesartan
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Mood
The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention
The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.
- Trial name
- NCT05318456
- Testing
- MoodElite T-4003-1, Comparator
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Chenland Nutritionals Inc.
Skin Fold, Skin Laxity
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA.
- Conditions
- Skin Fold, Skin Laxity, Skin Texture Disorder, Skin Depression
- Trial name
- NCT06000839
- Testing
- (D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique, (D28) Intradermal injection - micropapula technique
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Suisselle
Healthy Subjects, Depressive Disorder
GSK372475 Bioequivalence Study
The study is to show the new salt formulation of GSK372475 is equivalent to the old salt formulation of GSK372475.
- Trial name
- NCT00488098
- Testing
- GSK372475
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major Depression
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder.
- Trial name
- CALYPSO (NCT00345098)
- Testing
- SR58611A
- Where
- 13 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 704 people
- Sponsor
- Sanofi
Depression
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
- Trial name
- PET (NCT00832221)
- Testing
- SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety, tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in subjects with major depressive disorder
- Trial name
- MAD (NCT01774747)
- Testing
- DSP-1053
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC